Charles River Laboratories (CRL) Tops Q1 EPS by 21c; offers guidance
Tweet
Share
E-mailGet Alerts CRL Hot Sheet
Price: $288.50 -1.65%
Revenue Growth %: -4.3%
Financial Fact:
Net sales related to products: 132.87M
Today's EPS Names:
VIVO, BIOX, PMCB, More
Revenue Growth %: -4.3%
Financial Fact:
Net sales related to products: 132.87M
Today's EPS Names:
VIVO, BIOX, PMCB, More
Join SI Premium – FREE
Charles River Laboratories (NYSE: CRL) reported Q1 EPS of $2.27, $0.21 better than the analyst estimate of $2.06. Revenue for the quarter came in at $1.01 billion versus the consensus estimate of $992.31 million.
GUIDANCE:
Charles River Laboratories sees FY2024 EPS of $10.90-$11.40, versus the consensus of $11.02.
For earnings history and earnings-related data on Charles River Laboratories (CRL) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- EU proposes to curb Airbnb and short-term rentals amid housing shortage
- lululemon athletica (LULU) Tops Q2 EPS by $1.10, Cuts Guidance
- Asana, Inc. (ASAN) Tops Q2 EPS by 1c; offers guidance
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
